GlaxoSmithKline Pharmaceuticals Limited announced the outcome of its Board of Directors meeting held on August 3, 2026. The board approved the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. Additionally, the meeting saw the resignation of Mr. Subesh Williams as Non-Executive Director and the appointment of Ms. Karine J F Natland as a new Non-Executive Director. Mr. Bhushan Akshikar was also re-appointed as Managing Director for a two-year term.
Quarterly Financial Performance Announced
GlaxoSmithKline Pharmaceuticals Limited’s Board of Directors convened on August 3, 2026, to review and approve the financial results for the first quarter ending June 30, 2026. The company reported its Un-audited Standalone and Consolidated Financial Results for the period. The standalone results show a profit for the period of ₹25,333 lakhs, with revenue from operations at ₹92,442 lakhs. Consolidated figures indicate a profit for the period of ₹23,718 lakhs, with revenue from operations at ₹93,844 lakhs.
Key Management Changes
The board meeting also addressed significant changes in the company’s leadership. Mr. Subesh Williams (DIN: 07786724) stepped down as a Non-Executive Director from the closing hours of business on August 3, 2026. Concurrently, Ms. Karine J F Natland was appointed as a Non-Executive Director, effective from August 3, 2026, or upon obtaining her Director Identification Number (DIN), whichever is later. Ms. Natland brings extensive experience from her role as SVP Asia Pacific (APAC) at GSK and prior leadership positions at Organon, Merck, and MSD.
Managing Director Re-appointment
Furthermore, Mr. Bhushan Akshikar (DIN: 09112346) was re-appointed as the Managing Director of the Company. This re-appointment is for a term of two years, commencing December 1, 2026. Mr. Akshikar, who has been the Managing Director of GSK India since 2022, is recognized for his over 30 years of experience in the pharmaceutical industry.
Auditor’s Review
The financial results have undergone a limited review by the statutory auditors. The Independent Auditor’s Review Report confirms that based on their review, nothing has come to their attention that causes them to believe that the accompanying statements, prepared in accordance with Indian Accounting Standards and other generally accepted accounting principles, contain any material misstatement.
Source: BSE
